EXAS · As filed with the SEC
Exact Sciences cash flow statement, by fiscal year
The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2021 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (207,949) | (1,028,857) | (204,149) | (623,506) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
| Depreciation | — | — | 114,448 | 100,108 |
| Loss on disposal of property, plant and equipment | — | — | — | 1,863 |
| Unrealized (gain) loss on equity investments | — | — | — | 11,774 |
| Deferred tax benefit | — | — | — | (11,901) |
| Depreciation | 124,879 | 119,701 | — | — |
| Equity Securities, FV-NI, Gain (Loss) | 3,081 | (2,713) | 4,098 | — |
| Deferred tax benefit | — | — | (955) | — |
| Deferred tax benefit | (1,544) | (10,119) | — | — |
| Share-Based Payment Arrangement, Noncash Expense | 217,666 | 214,885 | 231,312 | 206,823 |
| Post-combination expense for acceleration of unvested equity | — | — | 0 | 0 |
| Realized (gain) loss on non-marketable investments | — | — | — | 10,000 |
| Loss on settlement of convertible notes | — | — | — | 0 |
| Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities | — | — | — | 7,127 |
| Amortization of premium on short-term investments | — | — | — | 1,845 |
| Gain on settlements of convertible notes, net | 0 | (10,254) | (10,324) | — |
| Amortization of Intangible Assets | 96,700 | 95,158 | 92,160 | 97,450 |
| Asset acquisition IPR&D expense | — | — | — | 0 |
| Asset acquisition IPR&D expense | — | — | 500 | — |
| Loss on sale of asset | — | 0 | 0 | 13,244 |
| Impairment of long-lived and indefinite-lived assets | 7,200 | 869,460 | 621 | 15,969 |
| Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff | 75,000 | — | — | — |
| Gain (Loss) On Contingent Consideration From Disposition Of Asset | 0 | (9,200) | (73,300) | — |
| Other Noncash Expense | — | — | 399 | — |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | 26,806 | (3,346) | (18,044) | (56,617) |
| Non-cash lease expense | 27,040 | 26,926 | 27,891 | 28,639 |
| Other Noncash Income (Expense) | 6,896 | (519) | — | — |
| Changes in assets and liabilities, net of effects of acquisition: | ||||
| Accounts receivable, net | (48,891) | (46,259) | (43,416) | 61,088 |
| Inventory, net | (3,772) | (34,911) | (7,690) | (13,231) |
| Operating lease liabilities | (28,541) | (25,783) | (26,701) | (20,646) |
| Accounts payable and accrued liabilities | 214,042 | 43,538 | 82,750 | (52,180) |
| Other assets and liabilities | — | — | — | (1,408) |
| Increase (Decrease) in Other Operating Assets | (5,794) | (2,323) | (11,618) | — |
| Increase (Decrease) in Other Operating Liabilities | (5,219) | 9,726 | 6,333 | — |
| Net cash provided by operating activities | 491,438 | 210,536 | 156,119 | (223,559) |
| Cash flows from investing activities: | ||||
| Purchases of marketable securities | (140,269) | (465,031) | (139,854) | (131,486) |
| Maturities and sales of marketable securities | 572,277 | 205,821 | 363,156 | 453,072 |
| Purchases of property, plant and equipment | (134,656) | (135,989) | (124,190) | (214,462) |
| Proceeds from Sale of Productive Assets | — | 0 | 0 | 25,000 |
| Proceeds From Contingent Consideration Receivable | 27,971 | — | — | — |
| Proceeds From Sale Of Investments In Privately-Held Companies | 0 | 0 | 19,794 | — |
| Payments to Acquire Other Investments | (55,499) | (1,731) | (16,564) | (42,823) |
| Business combination, net of cash acquired and issuance costs | 0 | 0 | (52,413) | (14,686) |
| Asset acquisitions, net of cash acquired | (75,000) | (45,000) | (500) | 0 |
| Other investing activities | 297 | (225) | 250 | (549) |
| Net cash provided by (used in) investing activities | 195,121 | (442,155) | 49,679 | 74,066 |
| Cash flows from financing activities: | ||||
| Proceeds from Accounts Receivable Securitization | — | 0 | 0 | 50,000 |
| Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised | 1,902 | 1,651 | 3,197 | 6,524 |
| Proceeds from sale of common stock, net of issuance costs | — | — | — | 0 |
| Proceeds in connection with the Company's employee stock purchase plan | 26,544 | 31,227 | 28,344 | 25,491 |
| Payments on settlement of convertible notes | — | — | — | 0 |
| Payments on construction loan | — | — | 0 | 0 |
| Proceeds from issuance of convertible notes | 0 | 266,750 | 137,976 | 0 |
| Repayments of Accounts Receivable Securitization | 0 | 50,000 | — | — |
| Repayments of convertible debt | 249,172 | — | — | — |
| Payment, Tax Withholding, Share-Based Payment Arrangement | 86,477 | — | — | — |
| Payment for Contingent Consideration Liability, Financing Activities | 19,000 | — | — | — |
| Other financing activities | (11,887) | (17,754) | (9,751) | (5,530) |
| Net cash provided by (used in) financing activities | (338,090) | 231,874 | 159,766 | 76,485 |
| Effects of exchange rate changes on cash and cash equivalents | 891 | (3,294) | 1,321 | 30 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 349,360 | (3,039) | 366,885 | (72,978) |
| Cash, cash equivalents, and restricted cash, beginning of period | 606,636 | 609,675 | 242,790 | 315,768 |
| Cash, cash equivalents, and restricted cash, end of period | 955,996 | 606,636 | 609,675 | 242,790 |
| Non-cash investing and financing activities: | ||||
| Property, plant and equipment acquired but not paid | 16,282 | 13,721 | 18,505 | 15,943 |
| Business acquisition contingent consideration liability | — | — | 0 | 4,600 |
| Stock Issued During Period, Value, Employee Benefit Plan | 43,943 | 40,550 | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest paid | 30,444 | 27,839 | 18,776 | 11,519 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.